SAFE-BioPharma Association Recertifies Adobe Software Used Throughout Pharmaceutical Industry

SAFE-BioPharma Association Recertifies Adobe Software Used Throughout Pharmaceutical Industry
Adobe Renews Its Commitment to Life Sciences with Recertification of Enterprise Products

FT. LEE, N.J.--(BUSINESS WIRE)--SAFE-BioPharma Association today announced from the 45th Annual Drug Information Association (DIA) Meeting that Adobe Systems Incorporated has recertified two software products used extensively in the pharmaceutical industry. The products -- Adobe® Acrobat® and Adobe Reader® with Adobe LiveCycle® Reader Extensions ES -- were found to be fully compliant with the SAFE-BioPharmaTM industry standard. The products were initially certified by SAFE-BioPharma two years ago and were recertified in 2008, along with Adobe LiveCycle Digital Signatures ES, which remains fully compliant with the SAFE-BioPharma standard.

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharmaTM digital identity and signature standard for the pharmaceutical and healthcare industries.

"As the top pharmaceutical companies continue to recognize the numerous advantages of adopting the SAFE-BioPharma standard and Adobe life sciences solutions, it is crucial that Adobe products remain compliant with the standard," said Melonie Warfel, director of worldwide standards and life sciences at Adobe. "Adobe and SAFE-BioPharma remain committed to helping life sciences organizations embrace technology to work faster and smarter."

The SAFE-BioPharma digital identity and signature standard is designed and used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It provides users with a secure, enforceable and regulatory-compliant way to verify identities of parties involved in electronic transactions and to apply their digital signatures to electronic documents. By using SAFE-BioPharma digital signatures, companies are able to dispense with paper originals and other cumbersome forms of backup.

"Adobe continues to play an important role in enabling pharmaceutical companies to bring better drugs to market faster and cheaper," said Mollie Shields-Uehling, president and chief executive officer, SAFE-BioPharma Association. "By recertifying these important digital identity and workflow solutions, Adobe shows its continued dedication to streamlining and securing pharmaceutical processes."

Adobe recertifies its products primarily used in the pharmaceutical industry through an inexpensive self-certification process introduced by SAFE-BioPharma.

Adobe Acrobat and Adobe Reader software enable biopharmaceutical and other professionals to reliably create, combine, and control Adobe PDF documents for easy, more secure distribution, collaboration, and data collection. Adobe LiveCycle solutions help accelerate the flow of information between people, documents, and enterprise processes while providing more control over sensitive information. Mixing the best of print and electronic communications, LiveCycle ES leverages the ubiquity of Adobe Flash and Reader to ensure that almost anyone can engage with information.

About SAFE-BioPharma Association

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharmaTM digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma's vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association's members include Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck, National Notary Association, Novartis, Pfizer, Premier Inc., Procter & Gamble, Roche, Sanofi-Aventis and ScheringPlough Organon. For more information, visit www.safe-biopharma.org.

SAFE-BioPharmaTM is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association. Adobe, Acrobat, Reader and LiveCycle are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.